

Charity number: 1123760
Company number: 6078396
(England and Wales)

British Society for Histocompatibility and Immunogenetics
Report of the Trustees and Unaudited Financial Statements
For the year ended 31 December 2024

British Society for Histocompatibility and Immunogenetics
Contents Page
For the year ended 31 December 2024

Report of the Trustees	1 to 4
Independent Examiner's Report to the Trustees	5
Statement of Financial Activities	6
Statement of Financial Position	7
Notes to the Financial Statements	8 to 13
Detailed Statement of Financial Activities	14 to 15

British Society for Histocompatibility and Immunogenetics
Report of the Trustees
For the year ended 31 December 2024

The Trustees, who are also directors for the purposes of company law, have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2024. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

The objects of the Society, as stated in its Memorandum of Association, are;

To promote and protect health for the public benefit in particular by:

(a) developing and maintaining good practice in Histocompatibility and Immunogenetics by ensuring the highest professional standards of competence;

(b) encouraging the advancement of scientific research and knowledge and of its application in all aspects of Histocompatibility and Immunogenetics and disseminating the useful results thereof.

The main activities of the society that contribute to the achievement of the objectives are;

Annual Conference

BSHI Annual Conference was held in person in 2024. The meeting provided an educational programme of lectures and seminars, including plenary lectures provided by world experts in the field of histocompatibility and Immunogenetics. Sessions were also held for BSHI Members to present short talks and case studies.

Two awards sessions were held. One for best abstract and one session for the Next Generation Scientist.

Objectives and aims

The trustees have considered the Charity Commission's guidance on public benefit, including the guidance 'public benefit: running a charity (PB2)'.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2024

ACHIEVEMENTS AND PERFORMANCE

Diploma and other training courses

BSHI supplies and administers a Diploma in Histocompatibility and Immunogenetics, to facilitate specialist learning in the field. Graduating diplomats received their awards at the Annual Conference.

A successful series of one and two day training courses were held to support BSHI Diploma, Trainee Clinical Scientists, Biomedical Scientists and those undertaking higher qualifications.

BSHI ran a higher training meeting for members considering taking the FRC Path examinations.

BSHI also administers a CPD scheme for the membership.

Special Interest Groups

The special interest groups were all busy this year providing educational workshops and forums for discussion between the different laboratories. The 3 active SIGs are the Antibody SIG, the Next Generation Sequencing SIG and the Haematopoietic Stem Cell SIG with meetings held this year around platelets and transplanting highly sensitised patients.

Bursaries and Grants

BSHI supplied bursaries to its members to attend scientific and educational meetings. These included the European Federation of Immunogenetics and British Society for Histocompatibility and Immunogenetics meetings.

The society also awarded the Julia Bodmer Travel Award, which allows a junior member of the society the opportunity to visit another laboratory to bring back some research ideas or new technology to their own laboratory. The recipient of the award presents their findings at the BSHI annual conference.

Representation to other professional bodies

The BSHI has nominated representatives to a number of other professional organisations and these representatives link to the BSHI Committee through the Professional Advisory Group. Elected members of BPAG are responsible for co-ordinating BSHI input to official working groups and documents.

BSHI is represented at the Association of Clinical Scientists, Clinical Pathology Accreditation UK Ltd, the Federation of Healthcare Science, the National External Quality Assurance Advisory Panel for Immunology, and the Royal College of Pathologists and NHSBT-ODT advisor groups.

Establishment and maintenance of appropriate standards within H & I is addressed through the BPAG. BPAG will interact with other professional organisations e.g. European Federation for Immunogenetics, British Transplantation Society as required and set up Standards Working Groups to address specific topics.

Online Virtual Conference Facility

BSHI provides virtual conference infrastructure via Microsoft Teams, enabling remote conferencing and education to take place and at the same time reducing waste and carbon impact.

Online Scientific Journals

BSHI continues to supply access to scientific literature that members do not readily have access to.

Publications

BSHI publishes a quarterly newsletter which is sent to all of the memberships. This contains reports from meetings, CPD journal based learning exercises and updates on developments within the society.

Online CPD Scheme

BSHI provides and manages online Continuing Professional Development, (CPD) scheme for its members via CPDMe.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2024

FINANCIAL REVIEW

Reserves

The overall reserves of the charity have again increased to £121,509 which leaves the charity in a strong position to continue to pursue its objectives for the foreseeable future.

Going concern

The trustees are confident that BSHI will be able to continue and pursue its objectives for the foreseeable future.

REFERENCE AND ADMINISTRATIVE INFORMATION

Name of Charity	British Society for Histocompatibility and Immunogenetics
Charity registration number	1123760
Company registration number	6078396
Principal address	C/O Executive Business Support Ltd City Wharf Davidson Road Lichfield Staffs WS14 9DZ

Trustees

The trustees and officers serving during the year and since the year end were as follows:

Richard Battle
Daniel Eggleston
Corinna Freeman
Helena Lee
Jessie Martin
Sarah Peacock
Emily Ryan
Olivia Shaw
Carla Rosser
(Appointed: 23 August 2024)
Rachel Smith
(Resigned: 31 January 2024)
Sarah Maxfield
(Appointed: 23 August 2024)
Rebecca McGuire
(Appointed: 02 February 2024)
Raymond Fernando
(Appointed: 02 February 2024)

Secretary Carla Rosser

Independent examiner Marie Hartwell
VESEY Accounting Services Ltd
Suite 1, Trinity House
33a Market Street
Lichfield, Staffs
WS13 6LA

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2024

Bankers

Barclays Bank Plc
Witham Business Centre
59 Newland Street
Witham
Essex
CM8 2AJ

Approved by the Board of Trustees and signed on its behalf by

10 September 2025

Corinna Freeman.....

British Society for Histocompatibility and Immunogenetics
Independent Examiners Report to the Trustees
For the year ended 31 December 2024

I report to the trustees on my examination of the accounts of the charitable company for the year ended 31 December 2024.

Responsibilities and basis of report

As the charity Trustees, who are also directors for the purposes of company law, are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiners qualified statement

I confirm that no other matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.

Marie Hartwell
VESEY Accounting Services Ltd
Suite 1, Trinity House
33a Market Street
Lichfield, Staffs
WS13 6LA

10 September 2025

British Society for Histocompatibility and Immunogenetics
Statement of Financial Activities (including Income and Expenditure Account)
For the year ended 31 December 2024

	Notes	Unrestricted funds £	2023 £
Income and endowments from:			
Charitable activities	3	102,368	80,889
Other trading activities	4	-	(426)
Investments	5	1,385	1,066
Total		103,753	81,529
Expenditure on:			
Charitable activities	6/7	(81,541)	(72,615)
Total		(81,541)	(72,615)
Net income		22,212	8,914
Reconciliation of funds			
Total funds brought forward		99,297	90,383
Total funds carried forward		121,509	99,297

British Society for Histocompatibility and Immunogenetics
Statement of Financial Position
As at 31 December 2024

	Notes	2024 £	2023 £
Fixed assets			
Tangible assets	14	-	29
		<u>-</u>	<u>29</u>
Current assets			
Debtors	15	29,305	19,380
Cash at bank and in hand		105,047	88,658
		<u>134,352</u>	<u>108,038</u>
Creditors: amounts falling due within one year	16	(12,843)	(8,770)
Net current assets		<u>121,509</u>	<u>99,268</u>
Total assets less current liabilities		<u>121,509</u>	<u>99,297</u>
Net assets		<u>121,509</u>	<u>99,297</u>
The funds of the charity			
Unrestricted income funds	17	121,509	99,297
Total funds		<u>121,509</u>	<u>99,297</u>

For the year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476,

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the Board and signed on its behalf by:

.....
Corinna Freeman
Trustee

10 September 2025

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements
For the year ended 31 December 2024

1. Accounting Policies

Basis of accounting

The financial statements have been prepared under the historical cost convention, except for investments which are included at market value and the revaluation of certain fixed assets and in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and the Companies Act 2006.

British Society for Histocompatibility and Immunogenetics meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Going concern

During 2024 BSHI was able to continue with its objectives with another successful year of member subscriptions, and the ability to hold the in person annual conference helped to improve income during the year. BSHI continues to seek cost effective ways of supporting their membership and the trustees are confident that BSHI will be able to continue and pursue its objectives for the immediate foreseeable future.

Incoming resources

All incoming resources are included in the statement of financial activities when the Charity is entitled to the income, and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Income from investments is included in the year in which it is receivable.

Resources expended

Liabilities are recognised as resources expended when there is a legal or constructive obligation committing the Charity to the expenditure:

Tangible fixed assets

Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Plant and machinery	25% Reducing balance
Computer equipment	25% Reducing balance
Motor vehicles	25% Reducing balance
Fixtures and fittings	25% Reducing balance

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2024

3. Income from charitable activities

	2024	2023
	£	£
Unrestricted funds		
<i>Charitable activities</i>		
Advertising	18,500	17,850
Subscriptions	27,030	26,080
Conference	3,243	2,800
Qualifications	43,735	24,045
	92,508	70,775
<i>Other member activities</i>		
Other member activities	225	-
Income from charitable activities	9,635	10,114
	9,860	10,114
	102,368	80,889

4. Income earned from other activities

	2024	2023
	£	£
Fund raising events	-	(426)
	-	(426)

5. Investment income

	2024	2023
	£	£
Unrestricted funds		
Bank interest receivable	1,385	1,066
	1,385	1,066

6. Costs of charitable activities by fund type

	2024	2023
	£	£
Unrestricted funds		
Charitable activities	34,044	25,627
Support costs	47,497	46,988
	81,541	72,615

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2024

7. Costs of charitable activities by activity type

	Activities undertaken directly	Support costs	2024	2023
	£	£	£	£
Support costs				
Charitable activities	34,044	47,497	81,541	72,615

8. Analysis of support costs

	2024	2023
	£	£
Charitable activities		
Management	444	-
Finance	1,359	1,288
Computer costs	188	560
Depreciation & amortisation	29	10
EBS Admin charges	32,628	31,697
International Journal of Immunogenetics	6,500	6,500
Print, post & stationery	28	53
Subscriptions	-	580
Telephone	309	67
Governance costs	6,012	6,233
	47,497	46,988

9. Net income/(expenditure) for the year

This is stated after charging/(crediting):

	2024	2023
	£	£
Depreciation of owned fixed assets	-	10
Accountancy fees	1,440	1,440
(Gain)/Loss on disposal of intangible fixed assets	29	-

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2024

10. Particulars of employees

2024	2023
0	0
<u>0</u>	<u>0</u>

12. Comparative for the Statement of Financial Activities

The comparative year values on the Statement of Financial Activities are for unrestricted funds.

13. Intangible fixed assets

	Intangible asset 1
Cost or valuation	£
At 01 January 2024	6,668
At 31 December 2024	<u>6,668</u>
Amortisation	
At 01 January 2024	6,668
At 31 December 2024	<u>6,668</u>
Net book values	
At 31 December 2024	<u>-</u>
At 31 December 2023	<u>-</u>

14. Tangible fixed assets

	Plant and machinery
Cost or valuation	£
At 01 January 2024	380
Disposals	(380)
At 31 December 2024	<u>-</u>
Depreciation	
At 01 January 2024	351
Disposals	(351)
At 31 December 2024	<u>-</u>
Net book values	
At 31 December 2024	<u>-</u>
At 31 December 2023	<u>29</u>

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2024

15. Debtors

	2024 £	2023 £
Amounts due within one year:		
Trade debtors	29,284	19,380
Prepayments and accrued income	21	-
	29,305	19,380

16. Creditors: amounts falling due within one year

	2024 £	2023 £
Trade creditors	11,403	7,330
Accruals and deferred income	1,440	1,440
	12,843	8,770

17. Movement in funds

Unrestricted Funds

	Balance at 01/01/2024 £	Incoming resources £	Outgoing resources £	Balance at 31/12/2024 £
<i>General</i>				
General	99,297	103,753	(81,541)	121,509
	99,297	103,753	(81,541)	121,509

Unrestricted Funds - Previous year

	Balance at 01/01/2023 £	Incoming resources £	Outgoing resources £	Balance at 31/12/2023 £
<i>General</i>				
General	90,383	81,529	(72,615)	99,297
	90,383	81,529	(72,615)	99,297

Purpose of unrestricted Funds

General

Unrestricted funds are funds that can only be used in accordance with the charitable objects and at the discretion of the trustees.

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2024

18. Analysis of net assets between funds

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
<i>General</i>				
General	-	-	121,509	121,509
	-	-	121,509	121,509

Previous year

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
<i>General</i>				
General	-	29	99,268	99,297
	-	29	99,268	99,297

19. Company limited by guarantee

British Society for Histocompatibility and Immunogenetics is a company limited by guarantee and accordingly does not have a share capital.

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities
For the year ended 31 December 2024

	2024 £	2023 £
INCOME AND ENDOWMENT		
Charitable activities		
Advertising (Charitable activities)	18,500	17,850
Subscriptions (Charitable activities)	27,030	26,080
Conference (Charitable activities)	3,243	2,800
Qualifications (Charitable activities)	43,735	24,045
Other member activities (Other member activities)	225	-
Income from charitable activities (Other member activities)	9,635	10,114
	102,368	80,889
Other trading activities		
Fund raising events	-	(426)
	-	(426)
Investments		
Bank interest receivable	1,385	1,066
	1,385	1,066
Total incoming resources	103,753	81,529
EXPENDITURE		
Charitable activities		
Cost of direct charitable activity (Charitable activities)	(34,044)	(25,627)
	(34,044)	(25,627)
SUPPORT COSTS		
Management		
Management (Charitable activities)	(444)	-
	(444)	-
Finance		
Finance (Charitable activities)	(1,359)	(1,288)
	(1,359)	(1,288)
Computer costs		
Computer costs (Charitable activities)	(188)	(560)
	(188)	(560)
Depreciation & amortisation		
Depreciation & amortisation (Charitable activities)	(29)	(10)
	(29)	(10)
EBS Admin charges		
EBS Admin charges (Charitable activities)	(32,628)	(31,697)
	(32,628)	(31,697)
International Journal of Immunogenetics		
International Journal of Immunogenetics (Charitable activities)	(6,500)	(6,500)

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities Continued
For the year ended 31 December 2024

	(6,500)	(6,500)
Print, post & stationery		
Print, post & stationery (Charitable activities)	(28)	(53)
	<u>(28)</u>	<u>(53)</u>
Subscriptions		
Subscriptions (Charitable activities)	-	(580)
	<u>-</u>	<u>(580)</u>
Telephone		
Telephone (Charitable activities)	(309)	(67)
	<u>(309)</u>	<u>(67)</u>
Governance costs		
Governance costs (Charitable activities)	(6,012)	(6,233)
	<u>(6,012)</u>	<u>(6,233)</u>
Total resources expended	<u>(81,541)</u>	<u>(72,615)</u>
Net Income	<u><u>22,212</u></u>	<u><u>8,914</u></u>